Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2367-2373

  Trefzer, Uwe ^a   Herberth, Gunda ^a   Wohlan, Karolina ^a   Milling, Annett ^a   Thiemann, Max ^a   Sharav, Tumenjargal ^a   Sparbier, Katrin ^a   Sterry, Wolfram ^a   Walden, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Clinical trial; Immune escape; Immune monitoring; Melanoma; T cell; Tumour vaccine

Indexed keywords

TUMOR ANTIGEN;

ANTIGENICITY; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; HUMAN; HUMAN CELL; HYBRID CELL; MELANOMA; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

EID: 14844337815     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.081     Document Type: Conference Paper

References (39)

1. S. Rosenberg Progress in human tumor immunology and immunotherapy Nature 411 2001 380 384
2. M.J. Smyth, D.I. Godfrey, and J.A. Trapani A fresh look at tumor immunosurveillance and immunotherapy Nat Immunol 2 2001 293 299
3. L. Novellino, C. Castelli, and G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 2004 Epub: 2004 Aug 7.
4. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, and J.S. Weber Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat Med 5 1999 677 685
5. R. Bucala, and C.N. Metz Immunosupressive factors in cancer G. Stuhler P. Walden Cancer Immune Therapy 2002 Wiley-VCH Weinheim, Germany 119 154
6. G.A. Ohnmacht, and F.M. Marincola Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma J Cell Physiol 182 2000 332 338
7. J. Wang, S. Saffold, X. Cao, J. Krauss, and W. Chen Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines J Immunol 161 1998 5516 5524
8. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
9. G. Stuhler, and P. Walden Recruitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes Cancer Immunol Immunother 39 1994 342 345
10. Y. Guo, M. Wu, H. Chen, X. Wang, G. Liu, and G. Li Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells Science 263 1994 518 520
11. Y. Akasaki, T. Kikuchi, S. Homma, T. Abe, D. Kufe, and T. Ohno Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model J Immunother 24 2001 106 113
12. J. Gong, D. Chen, M. Kashiwaba, and D. Kufe Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat Med 3 1997 558 561
13. J. Gong, D. Chen, M. Kashiwaba, Y. Li, L. Chen, and H. Takeuchi Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells Proc Natl Acad Sci USA 95 1998 6279 6283
14. S. Homma, G. Toda, J. Gong, D. Kufe, and T. Ohno Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice J Gastroenterol 36 2001 764 771
15. A. Kugler, F. Seseke, P. Thelen, M. Kallerhoff, G.A. Muller, and G. Stuhler Autologous and allogeneic hybrid cell vaccine in patients with metastatic renal cell carcinoma Br J Urol 82 1998 487 493
16. U. Trefzer, G. Weingart, Y. Chen, G. Herberth, K. Adrian, and H. Winter Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma Int J Cancer 85 2000 618 626
17. T. Kikuchi, Y. Akasaki, M. Irie, S. Homma, T. Abe, and T. Ohno Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells Cancer Immunol Immunother 50 2001 337 344
18. U. Trefzer, G. Herberth, K. Wohlan, A. Milling, M. Thiemann, and T. Sherev Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T cell and clinical responses in melanoma stage III and IV patients Int J Cancer 110 2004 730 740
19. L. Chen, S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, and J.A. Ledbetter Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71 1992 1093 1102
20. S.R. Bennett, F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath Help for cytotoxic-T cell responses is mediated by CD40 signalling Nature 393 1998 478 480
21. J.P. Ridge, F. Di-Rosa, and P. Matzinger A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell Nature 393 1998 474 478
22. S.P. Schoenberger, R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 1998 480 483
23. G. Stuhler, and P. Walden Collaboration of helper and cytotoxic T lymphocytes Eur J Immunol 23 1993 2279 2286
24. E. Borges, K.H. Wiesmuller, G. Jung, and P. Walden Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid J Immunol Methods 173 1994 253 263
25. C.N. Baxevanis, I.F. Voutsas, O.E. Tsitsilonis, A.D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor J Immunol 164 2000 3902 3912
26. U. Trefzer, and P. Walden Hybrid cell vaccines for cancer immune therapy Mol Biotechnol 25 2003 63 70
27. F. Sallusto, and A. Lanzavecchia Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med 179 1994 1109 1118
28. T.H. Scott-Taylor, R. Pettengell, I. Clarke, G. Stuhler, M.C. La Barthe, and P. Walden Human tumor and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines Biochim Biophys Acta 1500 2000 265 279
29. F. Kern, I.P. Surel, C. Brock, B. Freistedt, H. Radtke, and A. Scheffold T cell epitope mapping by flow cytometry Nat Med 4 1998 975 978
30. T. Linnemann, S. Tumenjargal, S. Gellrich, K. Wiesmuller, K. Kaltoft, and W. Sterry Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries Eur J Immunol 31 2001 156 165
31. K. el-Shami, B. Tirosh, E. Bar-Haim, L. Carmon, E. Vadai, and M. Fridkin MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope Eur J Immunol 29 1999 3295 3301
32. S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, and S.L. Topalian Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 1998 321 327
33. M.S. Mitchell, W. Harel, J. Kan-Mitchell, L.G. LeMay, P. Goedegebuure, and X.Q. Huang Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action Ann N Y Acad Sci 690 1993 153 166
34. J. Rice, S. Buchan, and F.K. Stevenson Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen J Immunol 169 2002 3908 3913
35. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, and R. Dummer Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 1998 328 332
36. F. Henry, O. Boisteau, L. Bretaudeau, B. Lieubeau, K. Meflah, and M. Gregoire Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines Cancer Res 59 1999 3329 3332
37. J. Galea-Lauri, D. Darling, G. Mufti, P. Harrison, and F. Farzaneh Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination Cancer Immunol Immunother 51 2002 299 310
38. D. Boczkowski, S.K. Nair, J.H. Nam, H.K. Lyerly, and E. Gilboa Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells Cancer Res 60 2000 1028 1034
39. T.L. Whiteside Immune cells in the tumor microenvironment G. Stuhler P. Walden Cancer Immune Therapy 2002 Wiley-VCH Weinheim, Germany 95 118